The Broader Implications of Biogen’s Divisive Alzheimer’s Drug

This post was originally published on this site

Good afternoon, readers! It was a big day in the Alzheimer’s treatment world as Biogen presented more detailed data on its controversial therapy aducanumab, which the drug giant hopes will become the first-ever Food and Drug Administration (FDA) …

Click here to read full article